Fate Therapeutics (FATE) Shares Outstanding (2012 - 2026)

Fate Therapeutics has reported Shares Outstanding for 15 years, with the latest figure at $116.3 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding rose 1.46% year-over-year to $116.3 million; the trailing twelve-month figure through Mar 2026 stood at $116.3 million (up 1.46% YoY), and the FY2025 full-year result was $115.4 million, up 1.26% from the prior year.
• Shares Outstanding for Q1 2026 stood at $116.3 million, up from $115.4 million in the prior quarter.
• The five-year high for Shares Outstanding was $116.3 million in Q1 2026, with the low at $2.8 million in Q3 2022.
• Historically, Shares Outstanding has averaged $101.1 million across 5 years, with a median of $113.8 million in 2024.
• Annual changes were most pronounced in 2023 — Shares Outstanding sank 97.16% — and 2024, when it surged 4026.18%.
• Fate Therapeutics' Shares Outstanding stood at $97.3 million in 2022, then slumped by 97.16% to $2.8 million in 2023, then surged by 4026.18% to $113.9 million in 2024, then increased by 1.26% to $115.4 million in 2025, then gained by 0.79% to $116.3 million in 2026.
• The last three Shares Outstanding figures came in at $116.3 million (Q1 2026), $115.4 million (Q4 2025), and $115.3 million (Q3 2025), per Business Quant data.